Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Conditions
Interventions
Cabozantinib (XL184) 140 mg
Cabozantinib (XL184) 60 mg
+2 more
Locations
49
Australia
St Leonards, New South Wales, Australia
Herston, Queensland, Australia
Kurralta Park, South Australia, Australia
Parkville, Victoria, Australia
Québec, Quebec, Canada
Toronto, Canada
Start Date
February 25, 2015
Primary Completion Date
July 15, 2020
Completion Date
January 1, 2035
Last Updated
September 2, 2025
NCT01109420
NCT01660984
NCT06814496
NCT06523582
NCT05534594
NCT01298323
Lead Sponsor
Exelixis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions